This week, nine Biotechnology stocks are improving their overall rating on Portfolio Grader. Each of these rates an “A” (“strong buy”) or “B” overall (“buy”).
ACADIA Pharmaceuticals (NASDAQ:ACAD) is making progress this week as its rating of C (“hold”) from last week increases to a B (“buy”) rating this week. ACADIA is a biopharmaceutical company that focuses on drug discovery and clinical development of small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. In Portfolio Grader’s specific subcategories of Earnings Momentum, Earnings Revisions, and Sales Growth, ACAD also gets A’s. Shares of ACAD have increased 30.8% over the past month, better than the 3.3% increase the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of ACAD stock.
Theravance (NASDAQ:THRX) earns a B this week, jumping up from last week’s grade of C. Theravance develops small molecule medicines for respiratory disease, bacterial infections, and gastrointestinal disorders. For more information, get Portfolio Grader’s complete analysis of THRX stock.
The rating of AMAG Pharmaceuticals (NASDAQ:AMAG) moves up this week, rising from a C to a B. AMAG Pharmaceuticals utilizes its proprietary technology for the development and commercialization of a therapeutic iron compound to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. Wall Street seems to agree with the upgrade and has propelled the stock up 16.8% over the past month. For more information, get Portfolio Grader’s complete analysis of AMAG stock.
NPS Pharmaceuticals (NASDAQ:NPSP) shows solid improvement this week. The company’s rating rises from a C to a B. NPS Pharmaceuticals is a biopharmaceutical company focused on the development of treatment options for patients with rare gastrointestinal and endocrine disorders and serious unmet medical needs. Wall Street has pushed the stock higher by 5% over the past month. For more information, get Portfolio Grader’s complete analysis of NPSP stock.
Sunesis Pharmaceuticals (NASDAQ:SNSS) is progressing from last week’s rating of B (“buy”) as the company improves to an A (“strong buy”) this week. Sunesis Pharmaceuticals is a clinical-stage biopharmaceutical Company which focuses on the discovery, development and commercialization of novel small molecule therapeutics for oncology. Investors have pushed the stock price up 49.2% over the past month. For more information, get Portfolio Grader’s complete analysis of SNSS stock.
Achillion‘s (NASDAQ:ACHN) ratings are looking better this week, moving up to a B from last week’s C. Achillion focuses on the discovery, development and commercialization of innovative treatments for infectious diseases. Investors seem to agree with the upgraded status of the stock, and have pushed the stock up 30% over the past month. For more information, get Portfolio Grader’s complete analysis of ACHN stock.
This week, Maxygen (NASDAQ:MAXY) pushes up from a C to a B rating. Maxygen is a biopharmaceutical company which researches and develops protein drugs. The stock currently has a trailing PE Ratio of 3.5. For more information, get Portfolio Grader’s complete analysis of MAXY stock.
Peregrine Pharmaceuticals (NASDAQ:PPHM) improves from a B to an A rating this week. Peregrine Pharmaceuticals is a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections. Wall Street has pushed the stock higher by 52.1% over the past month. For more information, get Portfolio Grader’s complete analysis of PPHM stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
